# Table of Contents

Vision, Mission, Values ............................................... 3  
A Letter from NBTS Board Chair ................................. 4  
A Letter from NBTS Chief Executive Officer ............... 5  
Progress in 2019 .......................................................... 7  
On The Front Lines: Dr. Edjah Nduom ....................... 10  
on the Battle Against Brain Tumors  
Glioblastoma Awareness Day ..................................... 12  
2019 Volunteer Leadership ........................................... 14  
Billi Ewing: From Tumor to Triumph ......................... 16  
Donor Honor Rolls 2019 ............................................. 18  
2019 NBTS Financials.................................................. 35
VISION

Conquering and curing brain tumors — once and for all.

MISSION

National Brain Tumor Society unrelentingly invests in, mobilizes, and unites our community to discover a cure, deliver effective treatments, and advocate for patients and care partners.

VALUES

Patients First
We are fiercely committed to providing a voice and community for all individuals impacted by brain tumors.

Constructive, Candid and Transparent
We practice fearless candor by being honest, accountable, and transparent in all that we do.

Committed to the Public Trust
We are prudent stewards of donors’ funds and conduct our organization openly, operate efficiently, and communicate frequently.

Positive (Can-do) Attitude
We believe a positive attitude is essential for achieving our goals.

Best-in-Class Science and Service to Our Community
We adhere to rigorous standards across our scientific and community initiatives.

Relentlessly Result Driven
We set aggressive goals, achieve measurable results, account for our work, and accurately report our progress. We drive positive change and have the courage to disrupt the system and take risks to achieve our goals.

Collaborative and Inclusive
We believe that working with others is critically important to achieving our mission.
Dear NBTS Community:

I’m so pleased and honored to be writing to you as the new Chair of the Board of Directors and as a fellow brain tumor survivor. Our mission and our cause are personal to me, and I intend to do everything in my power to ensure that National Brain Tumor Society is the best organization it can be for all of us.

In 2016, I was diagnosed with a subependymoma, and the tumor was removed through a very successful surgery at Massachusetts General Hospital, a clear brain tumor center of excellence. I am very fortunate, and realize that my health and the quality of treatment I received are the product and result of some of the work we do together through National Brain Tumor Society. Advocacy and philanthropy for brain tumor research, medical training and adequate health care delivery are the headwaters of the river that leads ultimately to better outcomes including cures. And I’ve come to understand that NBTS is a clear catalyst for that river to flow.

Indeed, 2019 was a year of significant progress as you will read in this Annual Report. Through NBTS, you advanced new research strategies to ignite the body’s own immune system to fight brain tumors, mobilized thousands of members of the brain tumor community to advocate, and honored countless loved ones who are battling brain tumors or passed away from this devastating disease. NBTS also was made stronger through the addition of new Board members including Amy Fenton, Dr. Edjah Nduom, Mike Smith and many new volunteers and teams.

I’m truly grateful for the work of staff and the board and to you as supporters, volunteers and donors.

With much gratitude,

Tom Roloff
Chair of the Board of Directors, National Brain Tumor Society
Dear NBTS Community:

Thanks to your support, National Brain Tumor Society completed a major transition under its strategic plan in 2019. We developed and put into place a new mission-delivery framework called Defeat, Connect and Change, designed to propel us forward toward our vision of conquering and curing brain tumors once and for all.

**Defeat**
The donor support and partnership of volunteers, including some of the world’s foremost scientific experts, led to our Defeat GBM Research Collaborative experiencing another extraordinary year of progress, while our Defeat Pediatric Brain Tumor Research Collaborative completed its first full year of funded work. Thanks to both of these flagship research programs, we were able to begin planning the broader next stage umbrella program platform, Defeat Brain Tumors, to bring forward the most treatments-focused work into new projects poised to accelerate laboratory research to clinical trials that give patients unique survival opportunities beyond the standard of care. One of the highlights of the year was the launch of the GBM AGILE clinical trial that NBTS is a supporter of. In 2019, we further focused the scope of research to the following themes: immunotherapy, DNA damage repair, tumor metabolism, precision medicine, and innovative clinical trial design. Going into 2020, this decision has yielded clearly focused projects worthy of immediate investment.

**Connect**
With advancements in neurosurgery to be realized, innovation in imaging, and new opportunities for clinical trials and off-label therapies, the importance of educating patients about treatment options early on at the point of diagnosis is more important than ever. In 2019, based on feedback from volunteers, NBTS began to design new programs aimed at empowering patients and care partners from time of diagnosis through their entire life as
a patient and survivor of a brain tumor. We brought on talented new staff capable of leading this work and continued to provide timely and trusted information to our community. We also brought together experts across government, industry, and hospitals with patients and families, to confront key challenges such as improving imaging and clinical trials for brain tumor patients, including those with brain metastases. We partnered with colleague and peer organizations to raise awareness and visibility. We also convened over 50,000 members of the brain tumor community across national and community events around the country, all united in our shared mission.

Change
Following up on the passage of the Childhood Cancer STAR Act in 2018, NBTS advocates tenaciously and successfully persuaded Congress to provide funding for STAR Act programs, and joined other groups to achieve another increase in federal funding for research. NBTS also led the brain tumor community in the creation of the first annual Glioblastoma Awareness Day, marked by a bipartisan resolution in the U.S. Senate and commitment from a bipartisan group of Senators.

An important part of NBTS’ success in 2019 was due to Sarah Durham’s leadership as our Chair of the Board of Directors. She did an outstanding job, and when her term concluded at the end of the year, she left NBTS even stronger, more prepared to realize our mission. She handed the gavel to another truly outstanding volunteer leader in Tom Roloff.

Thanks again to all of you. Every day we aim to earn your support and trust, and we are grateful to be a part of your lives.

David F. Arons, JD
Chief Executive Officer, National Brain Tumor Society
Through your generous support, in 2019 NBTS was able to make significant progress against all three of our mission-delivery strategies:

**Defeat**
- Supported the launch of GBM AGILE
- Funded $2.3 million in brain tumor research grants

**Connect**
- Launched Brain Tumor Support Conversations
- Convened over 50,000 people at regional events

**Change**
- Brought over 300 advocates to Capitol Hill to champion brain tumor funding and support
- Advocated for approx. $50 million more towards brain tumor research
Progress in 2019

While there is still much to accomplish to reach our ultimate goal of conquering and curing brain tumors, each of the achievements listed here tangibly advances brain tumor research and treatment development, patient access to care and support, and/or improves the lives of patients and their families.

Defeat
Accelerating Treatment-Focused Research

• Funded the discovery of a new and hoped-for clinical research strategy for immunotherapy in brain tumors
• Funded the discovery of a new approach to “supercharge” radiation treatment to help glioma patients
• Funded research that may have found a “missing link” between mutated genes in glioblastoma and nutrients tumor cells need to keep growing, which could be an important new drug target to treat glioblastoma and other tumors
• Invested a total of $1.25 million, together with other nonprofit advocacy groups and major gift support, to operationalize and launch GBM AGILE, the world’s first global “adaptive” clinical trial for brain cancer. Multiple GBM AGILE clinical trial sites opened in 2019.
• Established the Meningioma Research Fund, in partnership with the Brain Science Foundation (BSF), to raise and grant funds to advance meningioma research with the potential to translate into treatments that could improve survival and quality of life
• Established the Ependymoma Fund for Research & Education with the CERN Foundation
• Enabled NBTS to fund $2.3 million in research grants that span multiple tumor types, including the most deadly pediatric and adult brain tumors
Connect
Uniting the Brain Tumor Community

• Launched Brain Tumor Support Conversations, giving patients and families a new monthly peer-to-peer support and education opportunity
• Helped hundreds of patients and caregivers through personalized education and information, including our NBTS Clinical Trial Finder and quarterly Clinical Trial Reports
• Brought together more than 50,000 people at regional events, and thousands more through our Community Fundraising program, to honor loved ones and connect to key health and treatment information
• Showed brain tumor community strength through the Gray Nation Endurance program

Change
Improving the Brain Tumor Treatment & Research Environment

• Advocated successfully for approximately $50 million more from the federal government for brain tumor research for adults and children
• Championed a bipartisan Senate Resolution officially designating July 17, 2019 as the first-ever “Glioblastoma Awareness Day”
• Organized our largest ever Head to the Hill advocacy day on Capitol Hill, with more than 300 participants representing 37 states descending on Capitol Hill
• Helped advance the Palliative Care & Hospice Education and Training Act in the U.S. House of Representatives
• Successfully advocated for improved insurance coverage for a standard of care treatment in glioblastoma
At a young age, Edjah Nduom, MD, started telling friends and relatives that he would become a brain surgeon.

“I was the kid who was thrilled to get a science kit when I was growing up, because of all of the fun experiments that you could run,” says Dr. Nduom. “From the time I was little, I knew I wanted to do something challenging as a career, something that presented a new problem to solve on a daily basis.”

Achieving his childhood dreams, Dr. Nduom is now a neurosurgical oncologist in the Surgical Neurology Branch (SNB) of the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH). And, in 2019, he became one of the newest members of the NBTS Board of Directors.

“Joining the board of the National Brain Tumor Society has taken my dream of curing brain cancer one step further,” says Dr. Nduom. “Working with NBTS allows me to move beyond the confines of my own laboratory and help support research on brain tumors across the nation.”
“Joining the board of the National Brain Tumor Society has taken my dream of curing brain cancer one step further”

In addition to his clinical role in the Surgical Neurology Branch at the NIH, Dr. Nduom studies the use of immunotherapy for the treatment of brain tumors. “To run a lab on top of being a practicing physician can be a challenge, but it comes with advantages both scientific and personal,” says Dr. Nduom. “Being the one to see the patient and surgically resect the tissue that will be used in my experiments means I have a much more complete understanding of how our findings in the lab relate to the bigger picture of a patient’s overall care.”

Currently, Dr. Nduom is pioneering a new technique that simultaneously leverages his neurosurgical skills and his interest in harnessing the immune system to destroy cancer cells. He is the principal investigator of an early-stage clinical trial at the NIH that will monitor the effectiveness of a combination of two immunotherapy drugs in real-time through the use of “microdialysis catheters,” thin tubes places in the brain temporarily to monitor the ability of these treatments to kick the immune system into high-gear against the tumor cells.

Ultimately, Dr. Nduom and his team hope this innovative approach to treatment and clinical research will allow them to analyze, in near real-time, if changes occurring in and around the tumor are providing the right signals that an effective immune attack against the tumor is underway (in addition to standard evaluations of safety). With this information, Dr. Nduom and his team will gain early insight into the potential viability of these treatments, and if this approach is worth continuing to pursue, or if they should quickly pivot to another. If this new model of conducting an early-phase clinical trial is effective, it could provide a blueprint for the field to use more broadly in the future and advance new treatment options for glioma patients.

Working with talented and dedicated individuals like Dr. Nduom is critical to the National Brain Tumor Society’s mission and values of uniting the community, being collaborative and inclusive, and advancing best-in-class science and service to brain tumor patients and their families.
Glioblastoma (GBM), though it affects thousands of families each year, is technically a rare disease. It receives little of the same national attention as other, more prevalent cancers.

However, GBM entered into the national consciousness when, in 2018, Senator John McCain became the second prominent member of the United States Senate — following the passing of Senator Edward “Ted” Kennedy in 2009 — to die from this cancer.

Though McCain was a conservative Republican from the southwest, and Kennedy a liberal Democrat from the northeast, these two always shared a close bond in life, and are now inextricably linked by this devastating disease. This spurred the National Brain Tumor Society to reach out to Senator Lindsey Graham, a close friend of both Senators McCain and Kennedy, about working with NBTS to champion an effort to increase public awareness for glioblastoma by setting a day when the country could come together — across political divides — to commemorate, honor, and support those we’ve lost to this disease and those still facing its dire prognosis, along with all their loved ones and caregivers.

Senator Graham (R-SC) was able to bring together a bipartisan group of leaders in the Senate — including all four senators currently serving in the respective delegations that Kennedy
and McCain once led, Massachusetts and Arizona — to introduce Senate Resolution 245, declaring July 17, 2019, as the first-ever “Glioblastoma Awareness Day.”

The date was chosen to enable both the brain tumor community and Congress to have a date that could be its own, unique focal point for the nation’s attention to mobilize around the GBM cause and community. And with Senator Graham’s effort along with his distinguished co-sponsors for the bill - Senate Majority Leader Mitch McConnell (R-KY), Senators Elizabeth Warren (D-MA), Ed Markey (D-MA), Kyrsten Sinema (D-AZ), and Martha McSally (R-AZ) S.Res. 245 was passed by unanimous consent in the Senate on June 11, 2019.

“We ask all of America to join us in commemorating July 17, 2019, as Glioblastoma Awareness Day by paying tribute to those that have been taken by this disease, as well as the patients and families still coping with a diagnosis, and by uniting in a day of action and support to advance research and care so we can conquer and cure this disease once and for all,” NBTS CEO, David Arons, said in a statement at the time.

When the day arrived, the stories and voices of all of those who’ve been affected by GBM reverberated across the nation. Thanks to the brain tumor community’s fervent advocacy and action, the official #GBMDay social media hashtag was used in more than 500 posts and became a trending topic on Twitter. Glioblastoma Awareness Day was also featured in segments on leading media outlets like The View, ABC News, and the Today Show’s website.

The groundswell of awareness that was generated on the inaugural Glioblastoma Awareness Day served to establish a strong foundation for an annual commemoration that will now continue yearly to raise the collective consciousness in the U.S. about the urgent need to conquer and cure glioblastoma, and all brain tumors, once and for all.
2019 Volunteer Leadership

Board of Directors
Sarah Durham, Chair
Thomas Roloff, Vice Chair
John Frishkopf, Treasurer
Robert Burger, Clerk
Dave Brown
Rob Corrao
David Donabedian
Evanthia Galanis, MD
Ryan Lang
Autumn D. McDonald
Chandri Navarro, Esq.
Edjah Nduom, MD
Eric Olson, PhD
Stephen T. Sadler, JD
Liz Salmi
Michael Smith
Salo Zelermyer, JD
G. Bonnie Feldman, Non-Voting Co-Founder

Emeritus Board Members
Michael Corkin
Richard Genderson
Ken Grey
Steve Karol
Sheila Killeen
Jeffrey Kolodin
Michael Nathanson, JD, LLM
Susan Pannullo, MD
Cord Schlobohm, DMD
Rabbi Eric B. Wisnia
Charles B. Wilson, MD (deceased)

Scientific Advisory Council
Yancey Gillespie, PhD, Chair,
University of Alabama at Birmingham
Jill Barnholtz-Sloan, PhD, Case Western Reserve University
Dan Cahill, MD, PhD,
Massachusetts General Hospital
Joseph Costello, PhD, University of California, San Francisco
David Eisenstat, MD,
University of Alberta
Michael Lim, MD,
Johns Hopkins University
Duane Mitchell, MD, PhD,
University of Florida
Mario Suva, MD, PhD,
Massachusetts General Hospital
Ashley Sumrall, MD,
Levine Cancer Institute
Forest M. White, PhD,
Massachusetts Institute of Technology
In addition to the members of our Scientific Advisory Council and Defeat GBM Strategic Scientific Advisory Council, NBTS would like to recognize and express gratitude for those scientific and medical volunteers who volunteered and contributed expertise in 2019.

Terri S. Armstrong, PhD, NP, Neuro-Oncology Branch, National Cancer Institute
Scott Biller, PhD, Agios Pharmaceuticals
Timothy Cloughesy, MD, University of California, Los Angeles
Benjamin Ellingson, PhD, University of California, Los Angeles
Brenda Eustace, PhD, Vertex Pharmaceuticals
Evanthia Galanis, MD, Mayo Clinic
Mark Gilbert, MD, Neuro-Oncology Branch, National Cancer Institute/NINDS
Nancy Lin, MD, Dana-Farber Cancer Institute
Edjah Nduom, MD, National Institutes of Health
Eric Olson, PhD, Syros Pharmaceuticals
John Pollard, PhD, Vertex Pharmaceuticals
Liz Salmi, Patient Researcher OpenNotes/Beth Israel Deaconess Medical Center
Jeffrey Skolnik, MD, Inovio
Joohee Sul, PhD, U.S. Food and Drug Administration
W.K. Alfred Yung, MD, Anderson Cancer Center and NBTS Distinguished Scientific Advisor
Patrick Wen, MD, Dana-Farber Cancer Institute

Defeat GBM Strategic Scientific Advisory Council
Anna Barker, PhD, Arizona State University
Mitchel S. Berger, MD, FACS, FAANS, University of California, San Francisco
Lewis Cantley, PhD, Weill Cornell Medical College
Webster Cavenee, PhD, Ludwig Institute for Cancer Research, San Diego
William C. Hahn, MD, PhD, Dana-Farber Cancer Institute
W.K. Alfred Yung, MD, The University of Texas MD Anderson Cancer Center

In addition to the members of our Scientific Advisory Council and Defeat GBM Strategic Scientific Advisory Council, NBTS would like to recognize and express gratitude for those scientific and medical volunteers who volunteered and contributed expertise in 2019.

Terri S. Armstrong, PhD, NP, Neuro-Oncology Branch, National Cancer Institute
Scott Biller, PhD, Agios Pharmaceuticals
Timothy Cloughesy, MD, University of California, Los Angeles
Benjamin Ellingson, PhD, University of California, Los Angeles
Brenda Eustace, PhD, Vertex Pharmaceuticals
Evanthia Galanis, MD, Mayo Clinic
Mark Gilbert, MD, Neuro-Oncology Branch, National Cancer Institute/NINDS
Nancy Lin, MD, Dana-Farber Cancer Institute
Edjah Nduom, MD, National Institutes of Health
Eric Olson, PhD, Syros Pharmaceuticals
John Pollard, PhD, Vertex Pharmaceuticals
Liz Salmi, Patient Researcher OpenNotes/Beth Israel Deaconess Medical Center
Jeffrey Skolnik, MD, Inovio
Joohee Sul, PhD, U.S. Food and Drug Administration
W.K. Alfred Yung, MD, Anderson Cancer Center and NBTS Distinguished Scientific Advisor
Patrick Wen, MD, Dana-Farber Cancer Institute
When Billi Ewing’s doctor revealed the results of her MRI, she literally fell to her knees.

Diagnosed with a grade II atypical meningioma, Billi, a mother of three from Ohio, would require a complex 13-hour craniotomy to remove the tumor, followed by 33 rounds of radiation therapy to decrease the chances of experiencing regrowth.

While the treatment appears to have succeeded in preventing a recurrence, it left its mark — both literally and figuratively.

“Excruciating pain and facial disfiguration were my biggest issues immediately following surgery,” says Billi. “My right eye was swollen shut; my incision was as thick as my thumb and stretched from the center of my hairline to the bottom of my right ear lobe; my head was swollen and lopsided. I had a hard time looking at myself in the mirror for several months, fearing I would never recognize the person staring back at me again.”

Just as time was healing these wounds, a whole new slate of challenges arose: seizures, short term memory loss, fatigue, insomnia, tinnitus, headaches, and more.

To regain control over her life and a sense of normality, Billi set out to do everything she could to become an expert and strong advocate for the brain tumor community.

“I immersed myself in all things brain tumors, hoping to be the change I wanted to see by increasing awareness and to not let this experience get the best of me,” says Billi. “I was elated to find so many organizations and resources like the National Brain Tumor Society.
via social media, enabling me to become an active member of the brain tumor community instantaneously.”

Soon after connecting with NBTS on social media, Billi saw a post about Head to the Hill 2019. She was determined to attend.

“My heart wouldn’t let it go,” she says. “Advocacy at the legislative level was still on my brain tumor bucket list and here was my chance to check it off. So, I said a prayer, sent an email, and a few days later got the unbelievable news that I was chosen to be a Head to the Hill Scholarship recipient!”

Billi had already begun to rack up accomplishments that personified her approach to survivorship. She had started a support network called “Billi’s BElievers – From Tumor to Triumph;” captained teams in fundraising events; and secured proclamations officially acknowledging May as “Brain Tumor Awareness Month” in her township, city, and state; among other efforts. But it was attending her first Head to the Hill in 2019 that confirmed what she says is her “life’s new calling.”

“It was the moment that I saw the brain tumor community at its PEAK,” says Billi. “The advocacy training, the inspiring stories from other survivors, the heartfelt legacies many were valiantly upholding on behalf of their loved ones who passed on, the camaraderie, the sights, the sounds, the energy on Capitol Hill, the heartfelt conversations with our legislators and their aides – everything was just wow, Wow, WOW!”

Since departing from the Capitol last May, Billi has carried her experience forward.

“It increased my desire to get more people engaged beyond my local community,” says Billi, who is also a member of one of the largest sororities in the nation, Delta Sigma Theta Sorority, Inc. “By sharing my story and experience at Head to the Hill online, I discovered many of my sorors were brain tumor survivors or current patients. The lack of awareness coupled with the lack of representation in the African American community troubled me. We’ve sadly lost some since, but I’ve begun a movement within this sub-community of survivors, in hopes that we can unite and use our powerful voices and presence to effect real change at the national level.”

Billi will forever be grateful she was chosen as a Head to the Hill Scholarship recipient. And NBTS will always relish having the ability to offer assistance to deserving and special advocates like her, thanks to the generous support of our donors.

“Attending Head to the Hill last year, by far, was the most profound experience I’ve had as a brain tumor survivor and none of it would’ve been possible had I not been the recipient of a scholarship,” says Billi. “To serve as a delegate and share my story with our congressional leaders alongside other patients, survivors, and their loved ones, advocating for the entire brain tumor community, was life-changing.”
2019 SIGNATURE EVENTS

2019 Signature Event Top Fundraising Individuals

Bay Area Brain Tumor Walk: Leah Recht, $27,612
Boston Brain Tumor Ride: William Coffman, $33,405
Boston Brain Tumor Walk: Lindsey Harder, $30,935
Central New Jersey Brain Tumor Walk: Tara Laggini, $6,030
Charlotte Brain Tumor Race: Lea Williams, $11,771
Connecticut Brain Freeze: Cindee Muhl, $1,750

Delaware Brain Tumor Walk: Richard Burns, $4,650
Denver Brain Tumor Walk: Megan Boyer, $5,725
Florida Brain Tumor Race: Leanne Thomas, $3,101
Fort Worth Brain Tumor Walk: Kimberly Albro, $5,902
Long Island Brain Tumor Walk: Carissa Bentley, $19,192
Los Angeles Brain Freeze: Dean Fronk, $3,690
Maryland Brain Tumor Walk: Lisa Sliker, $6,552

New York City Brain Tumor Walk: Will Roth, $17,850
Northern NJ Mud Run & Walk: Jeff O’Brien, $3,178
Northwest Brain Freeze: Jo-Lynn Davis, $3,150
Northwest Brain Tumor Walk: Vona Weiss, $84,079
Orange County Brain Tumor Walk: Melissa Ernst, $24,268
Phoenix Brain Tumor Walk: Carlyn Ackerman, $5,521
Race For Hope DC Walk/Run: Stephen Conley, $98,305

Philadelphia Race for Hope Walk/Run: Timothy Lynch, $25,516
RVA Brain Tumor 5K: Robin Boisseau, $10,703
Sacramento Brain Freeze: Robert Jordan, $2,574
San Diego Brain Tumor Walk: Suzan Mahoney, $5,175
2019 Signature Event Top Fundraising Teams

$100,000+
- Cushman & Wakefield: $205,807
- ReMARKable strides: $172,820
- Survivors: $111,150

$50,000+
- Team Weiss: $86,689
- Chris Connelly Crushes Cancer: $75,034
- Kevin Strong: $69,621
- Team Mawn: $62,712
- HarderBetterFasterStronger: $60,982
- Lisa’s Riders: $55,320
- Team Kermit: $53,782
- David Cook’s Team for a Cure: $51,788

$25,000+
- William’s Warriors: $45,413
- #Olliestrong: $42,247
- Penn Neurosurgery Pioneers: $41,451
- Hope Brings Strength: $38,637
- Team Oligo: $36,190
- Hope by the Bay: $33,126
- Team Bald Bubby: $32,398
- High Hopes for a Cure: $31,764
- Kyle High Club: $31,404
- Sharing Hope: $30,283
- Team Jackie: $28,824
- SEAS THE DAY: $28,113
- Team Asher: $28,095
- ReMARKables: $28,010
- Uma: $27,879
- NBTS Board of Directors’ Team: $27,807
- Team Holly Grace: $27,594
- Noëlle’s Symphony: $27,224
- Team BT: $26,959
- Abby’s Avengers: $26,254
- All for Team Pamela Sue and Dana: $25,637
- #DréaStrong: $25,020

2019 Signature Event Top 10 Recruiting Teams

Train for Jay: 335 members
Jarema Strong: 204 members
Chris Connelly Crushes Cancer: 191 members
Kyle High Club: 185 members
Spain’s Brain Train: 165 members
Abby’s Avengers: 150 members
Survivors: 150 members
Kevin Strong: 148 members
Andrew’s Hulkamaniacs: 146 members
Team Holty: 140 members
2019 COMMUNITY EVENTS TOP FUNDRAISING EVENTS

$100,000+
2019 Team Billy Ride and Walk for Research: $131,568

$20,000+
2019 Madison Brain Tumor 5k: $72,448
2019 Rhode Island Brain Tumor Walk: $29,456
2019 Maryland Impact Golf: $28,811
2019 Jones’n for a Cure Golf Tournament: $26,000

$10,000+
2019 Mimosa March to Cure Brain Cancer: $25,026
2019 Bob Burns Memorial 5k: $25,000
2019 NBTS Charleston 3K Walk and Family Day: $22,237
2019 Tumor Takedown Tailgate: $21,289

2019 Shelby’s “Brewerfest” and Wine Tasting: $15,585
2019 Postmodern Jukebox Request-a-thon: $14,168
2019 Michael Cassidy Shamrock ‘N’ Run: $14,060
2019 Fight for the Brain Happy Hour: $12,561
2019 True Blue Shootout for a Cure Lacrosse Tournament: $11,600
2019 GBM Foundation Events: $11,000

2019 P&D Student Choreography Project: $16,112
2019 GRAY NATION ENDURANCE TOP FUNDRAISING INDIVIDUALS

$20,000+
Molly Griffiths, 2019 Boston Marathon: $25,990

$10,000+
Ron Clark, 2019 Falmouth Road Race: $11,530
Charlie Lonergan, 2019 Boston Marathon: $10,608
Michelle Mathai, 2019 TCS New York City Marathon: $10,125

$5,000+
Tarl Smith, 2019 Lake Placid Ironman 70.3: $8,938
Duba Family, 2019 Enchantment and Wonderland Trails Hike: $8,281
Jeff Barber, 2019 Medtronic Twin Cities 10-Mile: $8,140
Elizabeth Daniels, 2019 TCS New York City Marathon: $7,424
Andrea Levy, 2019 TCS New York City Marathon: $7,405

Sara Housley, 2019 TCS New York City Marathon: $7,183
Annie Pearlman, 2019 TCS New York City Marathon: $6,004
Alida Tieberg, 2019 Medtronic Twin Cities 10-Mile: $6,004
Glen Coblens, 2019 Ironman Arizona: $5,321
Joanna Grueneberg, 2019 TCS New York City Marathon: $5,198
Patrick Burke, 2019 TCS New York City Marathon: $5,152
### 2019 CORPORATE PARTNERS

<table>
<thead>
<tr>
<th>$50,000+</th>
<th>$10,000+</th>
<th>$25,000+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agios Pharmaceuticals</td>
<td>Alex.Brown</td>
<td>AbbVie Pharmaceuticals</td>
</tr>
<tr>
<td>Bayer Pharmaceuticals</td>
<td>Barrow Neurological</td>
<td>Cravath, Swaine &amp;</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Institute</td>
<td>Moore, LLP</td>
</tr>
<tr>
<td>Cushman &amp; Wakefield</td>
<td>Boston Bruins Foundation</td>
<td>Northern Bank &amp; Trust</td>
</tr>
<tr>
<td>Genentech</td>
<td>CapTech Ventures, Inc.</td>
<td>Company</td>
</tr>
<tr>
<td>Novocure</td>
<td>Celgene Corporation</td>
<td>Valero Energy Corporation</td>
</tr>
<tr>
<td>$25,000+</td>
<td>CoStar Realty Information</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cullather Brain Tumor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Quality of Life Center</td>
<td></td>
</tr>
<tr>
<td>$10,000+</td>
<td>Edison Oncology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Holding Corp.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eli Lilly and Company</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Highland Yard</td>
<td></td>
</tr>
<tr>
<td>$10,000+</td>
<td>Maryland Brain Tumor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment and Research Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Merck</td>
<td></td>
</tr>
<tr>
<td>$50,000+</td>
<td>Penn Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R&amp;R Mechanical</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Roark Law Office P.C.</td>
<td></td>
</tr>
<tr>
<td>$25,000+</td>
<td>Sharp Healthcare</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Showalter Construction Company, LLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Somersest Stores, LLC</td>
<td></td>
</tr>
<tr>
<td>$10,000+</td>
<td>Stifel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Susquehanna International Group, LLP</td>
<td></td>
</tr>
<tr>
<td>$100,000+</td>
<td>Rally Foundation for Childhood Cancer Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert I. Schattner Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert Lloyd Corkin Charitable Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Gwen L. Kosinski Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Students Supporting Brain Tumor Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Uncle Kory Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert I. Schattner Foundation</td>
<td></td>
</tr>
<tr>
<td>$50,000+</td>
<td>Yousefzadeh Family Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VCU Health System</td>
<td></td>
</tr>
<tr>
<td>$10,000+</td>
<td>Yousefzadeh Family Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VCU Health System</td>
<td></td>
</tr>
<tr>
<td>$25,000+</td>
<td>اهل Lloyd Corkin Charitable Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Gwen L. Kosinski Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Students Supporting Brain Tumor Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Wallace Landry Family Foundation</td>
<td></td>
</tr>
<tr>
<td>$10,000+</td>
<td>Josephine and Bernard Wilkinson US Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phyllis W. McGillicuddy Charitable Trust</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Hendrick Family Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Manning Family Foundation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Michaels Family Foundation</td>
<td></td>
</tr>
</tbody>
</table>
This list represents only a small portion of our dedicated and generous donors. All gifts, of all sizes, make a difference and are deeply valued by National Brain Tumor Society.

<table>
<thead>
<tr>
<th>CIRCLE OF PROGRESS</th>
<th>Lifetime Giving of $10,000 – $24,999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aileen Gregory</td>
<td></td>
</tr>
<tr>
<td>Alan J. Bernon</td>
<td></td>
</tr>
<tr>
<td>Alicia and T. L. Sean Cook</td>
<td></td>
</tr>
<tr>
<td>Alison and Greg Blank</td>
<td></td>
</tr>
<tr>
<td>Alison and Neal Goldner</td>
<td></td>
</tr>
<tr>
<td>Allison and Euan Thomson</td>
<td></td>
</tr>
<tr>
<td>Allyn and C. Bruce Campbell</td>
<td></td>
</tr>
<tr>
<td>Alysia Ferro</td>
<td></td>
</tr>
<tr>
<td>Amy and Barry Sylvetsky</td>
<td></td>
</tr>
<tr>
<td>Amy and David Donabedian</td>
<td></td>
</tr>
<tr>
<td>Amy and Richard Hurelbrink</td>
<td></td>
</tr>
<tr>
<td>Amy Null and Andrew Budson</td>
<td></td>
</tr>
<tr>
<td>Andrea Loew</td>
<td></td>
</tr>
<tr>
<td>Andrea Glick</td>
<td></td>
</tr>
<tr>
<td>Angela DeElse</td>
<td></td>
</tr>
<tr>
<td>Anita and Sidney Laham</td>
<td></td>
</tr>
<tr>
<td>Ann and John Baldwin</td>
<td></td>
</tr>
<tr>
<td>Ann H. Wiedie and Keith Hartt</td>
<td></td>
</tr>
<tr>
<td>Ann Marie Petach</td>
<td></td>
</tr>
<tr>
<td>Ann Oropeza</td>
<td></td>
</tr>
<tr>
<td>Anna and William Wilson</td>
<td></td>
</tr>
<tr>
<td>Anna and Daniel Bookin</td>
<td></td>
</tr>
<tr>
<td>Anne and Philip Bergan</td>
<td></td>
</tr>
<tr>
<td>Anne and Robert Fisher</td>
<td></td>
</tr>
<tr>
<td>Anne Pratt Jacoboski</td>
<td></td>
</tr>
<tr>
<td>Anthony Markel</td>
<td></td>
</tr>
<tr>
<td>Anthony Sasso</td>
<td></td>
</tr>
<tr>
<td>Ariel Bowers</td>
<td></td>
</tr>
<tr>
<td>Arsjad Rasjid</td>
<td></td>
</tr>
<tr>
<td>Arthur M. Winn</td>
<td></td>
</tr>
<tr>
<td>Autumn D. McDonald</td>
<td></td>
</tr>
<tr>
<td>Barbara and John Z. McDonald, D.O.</td>
<td></td>
</tr>
<tr>
<td>Barbara and Steven Janotta</td>
<td></td>
</tr>
<tr>
<td>Barbara Klein</td>
<td></td>
</tr>
<tr>
<td>Barbara Steger</td>
<td></td>
</tr>
<tr>
<td>Barry Small</td>
<td></td>
</tr>
<tr>
<td>Ben A. Beavers</td>
<td></td>
</tr>
<tr>
<td>Ben Rockwell</td>
<td></td>
</tr>
<tr>
<td>Benjamin Roussel</td>
<td></td>
</tr>
<tr>
<td>Bernard Hofmann</td>
<td></td>
</tr>
<tr>
<td>BethAnn Telford and Robert Latin</td>
<td></td>
</tr>
<tr>
<td>Betty Jane Roth</td>
<td></td>
</tr>
<tr>
<td>Billie C. Nelson</td>
<td></td>
</tr>
<tr>
<td>Blake Thomas</td>
<td></td>
</tr>
<tr>
<td>Bradley Page Dorman</td>
<td></td>
</tr>
<tr>
<td>Brandi and David Schwartzberg</td>
<td></td>
</tr>
<tr>
<td>Brett Johnson</td>
<td></td>
</tr>
<tr>
<td>Brett Sizemore</td>
<td></td>
</tr>
<tr>
<td>Bridget Hartman</td>
<td></td>
</tr>
<tr>
<td>Basehoar</td>
<td></td>
</tr>
<tr>
<td>Bruce and George Zallie</td>
<td></td>
</tr>
<tr>
<td>Bruce W. Bennett</td>
<td></td>
</tr>
<tr>
<td>C. Mark Pirrung</td>
<td></td>
</tr>
<tr>
<td>Cameron Reid</td>
<td></td>
</tr>
<tr>
<td>Candace and Gary Paris</td>
<td></td>
</tr>
</tbody>
</table>
Make it your legacy to conquer and cure brain tumors

Contact us at 617-237-1731 or mlacerda@braintumor.org to discuss how you can include National Brain Tumor Society in your estate plans

Carol and Allan Lewandowski
Carol and Donald McInnes
Carol and Jay Virshbo
Carol and Patrick Fitzgerald
Carol Church
Carolyn and Gregory Segall
Caroline Kim and Jonathan Paluga
Catherine Hay
Cathi and Thomas Magner
Chad Bernota
Chad Levitt
Charles Henry Smith III
Cheri and Roger Friedman
Chris and Doug Richards
Chris Bierly
Chris Bittman
Christine Crabtree
Christopher Braun
Christy Jones
Coaches Against Cancer
Colleen M. Tincer
Cora and Murray Simpson
Cynthia Peffers
Dana and Jeffrey Unger
Dana and Robert Emery
Dana White
Daniel C. Cook
Daniel S. Farb
Daniel Shrader
Danny VanMeter
David Andrews
David Arons
David Beddow
David Bender
David Fleishman
David Lendt
David Maltz
David R. Korn
David Stonehill
David Zallie
Davis Camalier
Deanna McIntire
Debbie and Mark Gladstone
Debbie Moormann
Deborah Westwood
DeDe and John Bradley
Delores and Lee Goodman
Denise and Francis Boucher
Denise Bednarek
Diana and Matthew Gordon
Diane Kranz
Disque Deane
Donna and Eric Brooks
Dorothy and Jack Ramsey
Dorothy Greene
Dorothy Mawn
Drana Prekelezaj
Drew Hagen
Edward Kaplan
Elaine Petach
Elena and Scott Lawlor
Elizabeth and Grant Hunt
Elizabeth Moore
Elizabeth Weatherman
and Andrew Duncan
Ellen and Steven
Branfman
Ellen G. Love
Emily and Reyn Parsons
Eric Aroesty
Eric Brooks
Eric Olson
Erika Long
Estelle S. Katcher
Ester Daskal
Finneas O’Connell
Franklin Ross
Fulton Liss
Gary Mather
Genie and Rocky Higgins
George F. Russell, Jr.
George Vanderheiden
Gerald I. Elovitz
Gregory Cafua
Gregory Margolies
Heather and Arthur Ross
Heather Davison
Heidi Moos
Helen and Michael Jaller
Holly and Joshua Bogart
Honey and Samuel
Shames
Hsien-Wei Tseng
In Memory of
Paul and Mary Revello
Irene and Frelan
Underwood
Jackie and James Katz
Jacqueline and Charles
Okosky
Jaime Peisach
James A. McDaniel
James Christopher
Doughan
James Duff
James Murphy
James Nottingham
James O’Malley
James Tennis
Jane Gumble and David Schroeder
Jane Karol and Howard Cooper
Janet and Filipo Tupua
Janet and James Wood
Janice K. Clifford
Jason Johnson
Jeanne and Paul Carroll
Jeff Bussgang
Jennifer and Jonathan Weinberg
Jerry Baker
Jerry Leo
Jill and Sherman Starr
Jill and Steve Karp
Jill and Thomas Wathen
Joan and Jack Beddow
Joan Karol and Irving Salloway
Joan M. Watson
Joe Scialabbo
Joel Levine
John A. Sobrato
John Carbahal
John Doerr
John H. Ewins
John Hicklin
John P. Fowler
John Regan
John Samuels
Jordan Hitch
Joseph Davis
Josh Goldfine
Joy and David Jenkins
Joy and Paul Fisher
Judith and Jack Remondi
Judith and Leonard DiCarlo
Judith Wells
Judy and Katie Swanson
Julie and Robert Adams
Karen and John Marshall
Karen and Marshall Varon
Karen Nusbaum
Katherine Johnson
Katherine L. Hufnagel
Kathleen and Richard Kelley
Kathleen Gallagher
Kathleen Mcdermott
Kathleen Moran
Kathryn and John Schlafer
Kathy Beck
Kathy Sanzo
Kathy Shreiner
Kay and Peter Bernon
Kelly Paul
Ken Caruso
Ken Testa
Kevin Hurley
Kim and Judith Davis
Kim Ostheimer
Kimberly Albro
Kristen Campana and John Longobardo
Kumiko and Joseph Dews
Kurt Krizan
Larisa Kure
Larry Oxenberg
Laura and Michael Slayman
Laura King Pfaff and Richard A. Pfaff
Lauri Union
Leah Recht
Leda Asmar
Leonard Green
Leverage Wines
Liebe G. Gregory
Lillian Corriea
Linda and Allan Gersten
Linda and Michael Frieze
Linda Bagley
Linda Fisher
Linda L. Sellaro
Lisa and Chris Peabody
Lisa and Darryl Maclean
Lisa and Kenneth Shapiro
Lisa J. Koch
Lisa Kaminsky-Millar
Lisa Yanolko-Moatz and Robert Moatz
Lois and Robert Annand
Lona and Alan Bridenbaugh
Lottie Talpis
Luann Dean
Lynn Slater
Lynn Tetenbaum and Steven Johnson
Maddie and Peter Jacobson
Madeline Leone
Marc Dixon
Marc M. Najarian
Margaret and Michael Smith
Maria Martorello
Marilu and Tim Maccarthy
Marilyn and Jim Mercer
Marilyn Mawn
Marilynn and Richard Abrams
Marjorie Jelin
Marjorie Zapruder
Mark Schlobohm
Marla and Gary Gross
Martin J. Mannion
Mary Alice B. Schaff
Mary and Richard Abbey
Mary and Stephen Lanctot
Mary Sue and Brian Marshall
Mary-Ann Moalli
Matthew Gordon
Maura and Brian Kneafsey
Maureen McDarby and William Ziebur
Meghan Whaley
Melinda and Jeff Fager
Melinda Dabbiere
Melissa and Frances Hopkins
Melissa and Jonathan Silver
Melissa Mannion
Michael Allen
Michael Johnson
Michael Rudman
Michael Thonis
Michaela Cachia
Michelle Young
Monty Bennett
Morty Gudelsky
Nadia Ramadan
Nadine Berman
Nancy and Ron Rovansek
Nancy Dickmeyer
Nancy Dougherty
Nancy E. Pfund
Nancy Samit
Natalie and Eric Boyd
Neal Levitan
Olivia Brown
Patricia and Thomas Plant
Patrick Herron
Paul Calvino
Paul Sasso
Paul Teti
Pauline Elkin
Peggy and John Mooney
Peggy DeBerry
Peggy Wilson
Penny and David Alschuler
Peter A. Wright
Peter Lewis
Phillip Staples
Phyllis and Robert Yawitt
Priscilla A. Partridge
Pushpa Patel
Randall O'Deneal
Rebecca and Glenn Asher
Rebecca and Michael Neidorf
Rebecca Newland
Regina Coppens and Steven Buchsbaum
Renee Limpawuchara
Rhoda Farber
Richard Burns
Richard Forde
Richard Granoff
Richard M. Lappin
Richard Osney
Richard Schifter
Richard Weschler
Rick A. Stacy
Rob Lazarowitz
Robert E. Freitas
Robert Greenhill, Jr.
Robert Hisaoka
Robert J. Drabkin
Robert L. Salomon
Robert M. Kern
Robert Rosen
Robert Slyker
Robin and Lawrence Gitlitz
Robin and Michael Winton
Robin and Tom Oswold
Robyn and Bill Collins
Ronald Rubin
Ronald Simon
Roni and Lawrence Kosow
Ronna Martin
Ronnie Bretholtz
Rosalyn and Alan Geller
Rose Heide and Gary Sweet
Roy Kapani
Russell Deyo
Ruth Curtis
Ryan Steel
Sabrina and Robert Nicholson
Sandra Simon
Sarah Stokes and Robert Luoma
Sasha Dorman and Seth Hamalian
Scott Mack
Serene Smith
Sharon Campbell
Shauna Pendleton
Shawn M. Herlihy
Shelley and David Wolfberg
Shelley and Jonathan Isaacson
Shepard Spunt
Sheri Leiter
Sheryl and Craig Bacharach
Sheryl Sandberg
Sidney Suggs
Sinesia and William Karol
Sonia and Milton Greenberg
Sonja and Phillip Plant
Staci and Rick Genderson
Stan Oaks
Stella Tavilla
Stephanie and John Connaughton
Stephanie Pechner
Stephen Mugford
Stephen O'Brien
Stephen Schoener
Steve Barnes
Steven Brown
Steven S. Fischman
Sue and Sheldon Lewis
Susan and Derek Arndt
Susan Baucom
Susan Lasher
Suzanne and Jeffrey Bloomberg
Suzanne Peck
Tasneem Ghuman
The Family of Lionel Chaiken
Theresa Carey
Thomas Coogan
Thomas Karol
Timothy Donovan
Tomoko Ozawa
Tracy Fischer and Cary Geller
Tracy Milcendeau
Valerie Farkas
Vangel R. Zissi
Venita Kent-Basham
Vincent Bilinsky
Vincent Browning
Vivian and Barry Bornfriend
W. Graham Smith
Wayne Long
Wendy and Lawrence Pizzi
Wendy Leuchter
Whitney and Adam Hayden
William H. Connelly, Jr.
William Moseley
William Rucker
William W. Beddow
Woodworth Clum
Woody Peterson
Zach Casagrande

**CIRCLE OF CHANGE**
**Lifetime Giving of $25,000+**

Albert Dwoskin
Alison Ross
Allison Bishop
Amy and Steven Halvorsen
Amy and William Reller
Andrea and Bryon Sheets
Andrea J. Schrier-Miller
Andy Lantz
Ann Gordon and Alan Lefkof
Annette Rado
Arlene Roth
Arthur Kern
Ashley and Alan Dabbiere
Barbara and Donald Janower
Barbara Roche
Barbara Shapiro
Bill Elovitz
Bonnie and Donald Dwares
Bonnie and Jon Rotenberg
Bonnie Feldman
Bridget and Patrick McCall
Caren and Barry Glassman
Carol and Garold Brown
Carol and Thomas Brandi
Carole Sclafani
Catherine and Michael Podell
Catherine Mannion
Catherine Wytzka
Cecilia and John Farrell
Charles A. Young, III
Charlotte and Stacey Case
Charlotte Florence
Chris and George Bein
Christopher Brown
Cindy and Roy Villarreal
Constance Forchheimer Heller
Cynthia and Gary Wengerter
Dana and Vince Vannelli
Daniel Beekhuizen
Daniel Bukkhegyi
Daniel Greiff
David Lake
Dawn Bauleke
Deborah and Ira Palgon
Deborah and Ronald Ratner
Dee and Lloyd Benedict
Denise and Jeffrey Bein
Dolores and Jim Claeys
Eileen Roche
Eliane and Gary Markoff
Elisha Wiesel
Elizabeth and Mark Moragne
Ellen and Stephen Conley
Ellen Newman
Eric Slifka
Evelyn Goldfine
Frederick Samaha
Gerald Greco
Geraldine Gerson
Gina and Charles Nash
Gina and Scott Memmott
Gregory Kovacs
Harry Goulder
Hazel and Kenneth Dreyer
Heidi and Nathaniel Leonard
Hope and Gary Schwab
Ingeborg and Cord Schlobohm
James Conley Jr.
James Curtis III
James Hornthal
James Pemberton
James Richter
Jamie McGuire
Jan McCormack
Janet and Michael Mulvaney
Janice and Steve Hamill
Janie Sweeney
Jean and Steve Case
Jeannette and Richard Hollow
Jeff Davis
Jeffrey Kolodin
Jen and Bryan Hume
Jillian Roth
Jim Doughan
Joan Griffin
Sally and Steven Lamb
Sally Curtin
Sandra and Mark Kramer
Sarah Durham and Craig Winer
Sharon and Joe Lamb
Sheila and Robert Conneely
Sheila Killeen
Sheri Soboardo Brisson
Sondra Rudofsky
Stephanie and Leonard Farber
Stephen Reller
Steve Newman
Steven Connolly
Susan Tavilla
T. Conrad Wetterau
The Kwinn Family
Thomas Enraght-Moony
Tom Rollins
Valerie Hurley and John Kern
Vincent Browning
Wayne Conrad
William Coffman
William Dudley
William Hearst
William V. Fogg

CATALYST CIRCLE

Members of the Catalyst Circle have made leadership gifts in support of the Nathanson Family Catalyst Fund for Brain Tumor Research. www.NathansonFund.org.

Amy Null and Andrew Budson
Andrew Merken
Focus Financial Partners
Jeanie and Jim Kirkiles
Judi and Edward Zuker
Julie and Michael Durbin
Lauren and Michael Corkin
Lowenstein Sandler LLP
Martin Bicknell
Melanie and Steve Sadler
Michael and Dawn Nathanson
Michael Goss
Ronald Rubin
Sarah Durham and Craig Winer
Sentinel Benefits and Financial Group
Shikiar Family Foundation
2019 NBTS FINANCIALS

- 12% Fundraising
- 17% Research Grants
- 2% General and Admin
- 86% Total Program Expenses
- 70% Other Program Expenses
### Statement of Financial Position

<table>
<thead>
<tr>
<th>Assets</th>
<th>12/31/2019</th>
<th>12/31/2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$6,422,000</td>
<td>$3,088,930</td>
</tr>
<tr>
<td>Investments</td>
<td>849,578</td>
<td>581,854</td>
</tr>
<tr>
<td>Pledges receivable, net</td>
<td>289,200</td>
<td>83,000</td>
</tr>
<tr>
<td>Prepaid and other current assets</td>
<td>176,834</td>
<td>161,621</td>
</tr>
<tr>
<td>Long-term assets</td>
<td>50,356</td>
<td>53,538</td>
</tr>
<tr>
<td>Total assets</td>
<td>$7,787,968</td>
<td>$3,968,943</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$439,129</td>
<td>$384,406</td>
</tr>
<tr>
<td>Research grants payable</td>
<td>500,000</td>
<td>1,250,000</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>84,539</td>
<td>99,601</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>1,023,668</td>
<td>1,734,007</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net assets</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions</td>
<td>2,339,672</td>
<td>980,981</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>4,424,628</td>
<td>1,253,955</td>
</tr>
<tr>
<td>Total net assets</td>
<td>6,764,300</td>
<td>2,234,936</td>
</tr>
</tbody>
</table>

| Total liabilities and net assets | $7,787,968 | $3,968,943 |

### Statement of Activities

<table>
<thead>
<tr>
<th>Revenue</th>
<th>12/31/2019</th>
<th>12/31/2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events, grants, and contributions</td>
<td>$13,705,221</td>
<td>$10,874,060</td>
</tr>
<tr>
<td>Bequests</td>
<td>250,000</td>
<td>137,159</td>
</tr>
<tr>
<td>Donated goods and services</td>
<td>221,747</td>
<td>90,783</td>
</tr>
<tr>
<td>Other income</td>
<td>33,770</td>
<td>28,476</td>
</tr>
<tr>
<td>Total revenue</td>
<td>14,210,738</td>
<td>11,130,478</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Operating expenses</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel</td>
<td>4,504,961</td>
<td>3,639,275</td>
</tr>
<tr>
<td>Research grants</td>
<td>1,592,534</td>
<td>2,922,375</td>
</tr>
<tr>
<td>Special events</td>
<td>885,883</td>
<td>897,653</td>
</tr>
<tr>
<td>Professional services</td>
<td>685,166</td>
<td>658,047</td>
</tr>
<tr>
<td>Travel</td>
<td>254,976</td>
<td>278,358</td>
</tr>
<tr>
<td>Systems and technology</td>
<td>273,007</td>
<td>275,445</td>
</tr>
<tr>
<td>Other expenses</td>
<td>1,544,971</td>
<td>1,618,976</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>9,741,498</td>
<td>10,290,129</td>
</tr>
</tbody>
</table>

| Changes in net assets from operations | 4,469,240 | 840,349 |

| Endowment contributions and other revenue | 60,124 | 192,126 |

| Change in net assets | $4,529,364 | $1,032,475 |